Low-risk prostate cancer patients face overtreatment

August 15, 2006

Many low-risk prostate cancer patients are being overtreated and might fare better if doctors monitored the cancer until treatment was necessary, a new study reports in the August 16 issue of the Journal of the National Cancer Institute.

Past recommendations for early-stage prostate cancer patients involved prostate removal rather than monitoring the cancer's progress until treatment is necessary. But more recently, cancers are being detected at earlier stages, and reports that low-risk patients are being treated aggressively have made researchers suggest such treatment may not be the best solution. New studies suggest that aggressive treatment does not improve survival benefits and may harm patients' health.

John T. Wei, M.D., of the University of Michigan in Ann Arbor, and colleagues identified 71,602 men over age 70 diagnosed with prostate cancer between 2000 and 2002. They determined how many men were treated with various therapies, including surgery and radiation, and how many times the "wait and see" approach was used.

The authors identified 24,825 men with lower-risk prostate cancers, 13,537 of whom underwent immediate treatment with radiation or prostate removal. Assuming waiting for treatment would have been the best approach for these cancers, the authors found that 10% of patients were overtreated with prostate removal and 44% with radiation therapy. Wei and colleagues suggest waiting until treatment is necessary may reduce overtreatment for patients with low risk prostate cancer.

They write, "Efforts to reduce overtreatment should be a clinical and public health priority."
  • Nicole Fawcett, 734-764-2220, nfawcett@umich.edu

    Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134-1141.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

    Journal of the National Cancer Institute

    Related Prostate Cancer Articles from Brightsurf:

    Low risk of cancer spread on active surveillance for early prostate cancer
    Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

    ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
    A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

    Major trial shows breast cancer drug can hit prostate cancer Achilles heel
    A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

    The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
    Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

    Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
    Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

    First prostate cancer therapy to target genes delays cancer progression
    For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

    Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
    University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

    CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
    The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

    Distinguishing fatal prostate cancer from 'manageable' cancer now possible
    Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

    Researchers find prostate cancer drug byproduct can fuel cancer cells
    A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

    Read More: Prostate Cancer News and Prostate Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.